1. Celgene is Buying Cancer Drugmaker Juno Therapeutics for $9 Billion

    Celgene is Buying Cancer Drugmaker Juno Therapeutics for $9 Billion
    • Celgene is acquiring Juno Therapeutics, a company developing personalized cancer treatments in a deal worth $9 billion.
    • It's the second deal in 2018 for the biotech giant, which has been under pressure from investors.
    • The highly personalized treatments Juno makes, called CAR T-cell therapy, are at the beginning of what some are calling "a big new field of medicine...
    Read Full Article

    Login to comment.

  1. Categories

    1. BoardProspects Features:

      BoardBlogs, BoardKnowledge, BoardMoves, BoardNews, BoardProspects Announcements, BoardProspects CEO, CEO Blog, In the News, Partner Publications, Sponsored Content
  2. Quotes

    1. The acquisition of Juno builds on our shared vision to discover and develop transformative medicines for patients with incurable blood cancers.
  3. Topics Mentioned

  4. Authors